Exelixis Inc

+0.47 (+1.90%)
4:00:00 PM EDT: $25.17 +0.01 (+0.04%)
Products, Regulatory

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival In Phase 3 Trial In Patients With Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

Published: 12/21/2020 16:21 GMT
Exelixis Inc (EXEL) - Exelixis Announces Cabozantinib Significantly Improved Progression-free Survival in Cosmic-311 Phase 3 Pivotal Trial in Patients With Previously Treated Radioiodine-refractory Differentiated Thyroid Cancer.
Exelixis Inc - Cabozantinib Reduced Risk of Disease Progression Or Death by 78%.
Exelixis Inc - Exelixis Will Discuss Trial Results and Regulatory Filing Plans With U.S. Food and Drug Administration.
Exelixis Inc - Safety Profile Was Consistent With That Previously Observed for Cabozantinib.